Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ME3208 in steroid-dependent or steroid-resistant chronic graft-versus-host disease
jRCT2011210041Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of BJTJ-0045 in chronic graft-versus-host disease (cGVHD), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Best overall response rate and Safety. Started Dec 2021; status: completed.
02
Drugs
BJTJ-0045
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2011210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210041.